Latest From Scancell Ltd.
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Scancell, which develops immunotherapies for the treatment of cancer, has appointed Dr Sally Adams to its board of directors as development director – effective 1 May 2014. Dr Adams has worked as a consultant at Nottingham, UK-based Scancell since 2008. Previously, she was head of neurology and virology at British Biotech, and development director at Neures.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Scancell Ltd.
- Senior Management
Cliff Holloway, PhD, CEO
Sally Adams, PhD, Dev. Dir.
Lindy Durrant, PhD, CSO
Keith Green, Dir., Fin. & Admin.
- Contact Info
Phone: (44) (0) 1865 338 069
John Eccles House/Robert Robinson Ave.
P.O. Box 6457 Oxford, OX4 4GP
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.